Guillain-Barré syndrome (GBS) is an acute polyneuropathy with a variable degree of Another prognostic model (Erasmus GBS Outcome Scale) has been. e.g., the Medical Research Council Scale. Grade 5: outcome, caregivers, including medical professionals, may help Erasmus GBS Prognosis Score. 1. Abbreviation / Long Form: EGOS / Erasmus GBS Outcome Scale 3, , IVIG treatment and prognosis in Guillain-Barre syndrome. GBS, IVIG.
|Published (Last):||21 February 2007|
|PDF File Size:||19.42 Mb|
|ePub File Size:||7.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
The disease is mostly preceded by an infection and generally runs a monophasic course. Rather surprisingly, steroids alone are ineffective. Mainly for practical reasons, IVIg usually is the preferred treatment. Additionally, many patients have pain, fatigue or other residual complaints that may persist for months or years.
Pain can also be very confusing in making the diagnosis, especially when it precedes the onset of weakness. Advances in prognostic modelling resulted in the development of a simple prognostic scale that predicts the chance for artificial ventilation, already at admission; and in an outcome scale that can be used to determine the chance to be able to walk unaided after 1, 3 or 6 months.
GBS patients with a poor prognosis potentially might benefit from a more intensified treatment. This study is currently going on.
Modified Erasmus GBS Outcome Score (EGOS) at day 7 of admission | Calculate by QxMD
The international GBS outcome study IGOS is a new worldwide prognostic study that aims to get further insight in the immune pathophysiology and outcome of GBS, both in children and adults.
Hopefully these and other studies will further help to improve the understanding and especially the outcome in erasmux with GBS. They reported the combination of increased protein concentration with a normal cell count in the CSF, or albuminocytological dissociation, which erzsmus the condition form poliomyelitis.
Click here to see the Library ].
GBS most frequently is a post-infectious disorder, mostly with Campylobacter jejunicytomegalovirus, Epstein-Barr virus or M. In typical cases, among the first outcpme are pain, numbness, paraesthesia, or weakness in the limbs. The main features of GBS however are rapidly progressive bilateral and relatively symmetric weakness of the limbs with or without involvement of respiratory or cranial nerve-innervated muscles.
Sca,e Click here to see the Library ]. Patients then have a plateau phase of variable duration ranging from days to several eramsus or months. This phase is followed by a recovery phase of variable duration Figure 1.
Moreover, many patients remain otherwise disabled or severely fatigued. The diagnosis of GBS is often straightforward, especially when weakness is preceded with an infection within 1—3 weeks from onset box 1. Therefore, several features especially should raise doubt about the diagnosis box 2.
Several disorders or conditions that may mimic GBS need to be excluded or made unlikely before the diagnosis of GBS can be made box 3. CSF examination is especially helpful to rule out other causes of weakness, for example Lyme disease or HIV-related radiculitis, both associated with increased number of mononuclear cells. If there is an increased cerebrospinal fluid total protein without cellular reactionthis may help making the diagnosis, especially when there are some none-typical features.
EMG is especially helpful when it shows signs of a polyneuropathy in clinically not yet involved areas, for example when it shows signs of a polyneuropathy in the arms in patients with weakness only in the legs. Anti-ganglioside antibody and neuropathy: The results of these anti-ganglioside antibody essays however may last several days or weeks making these tests not always very suitable for use in clinical practise.
A recent paper lutcome on yet published and well-discussed data proposed new criteria for GBS and Miller-Fisher syndrome. Whether these Brighton criteria also work wrasmus clinical practise now needs further evaluation. To further move on with the criteria for GBS, it especially would be helpful to have access to new carefully prospectively gathered data on a large group of well-described and followed GBS patients.
This preferentially includes both mildly and severely affected GBS patients, both children and adults, scxle patients from various regions around the globe so to include reasonable large numbers of both AIDP and AMAN cases.
These new data potentially give relevant information, also on less frequently encountered clinical subgroups, including on patients who do not fulfil all standard diagnostic criteria usually required to be randomized in controlled trials, e.
This would help to have better insight in the complete spectrum of GBS. Patients with GBS especially need excellent multidisciplinary care to prevent and manage the potential fatal complications.
This means at least the kutcome measurement of vital capacity and respiratory frequency, and timely transfer oucome an intensive care unit when indicated box erasmua.
Among other issues that need attention already early in the course of disease are prophylaxis for deep vein thrombosis, cardiac and hemodynamic monitoring outcoe other symptoms of autonomic dysfunctionpain management, management of possible bladder and bowel erasmuw, psychosocial support and rehabilitation. CD Click here to see the Library ]. The usual regimen is a five times PE during 2 weeks, with a total exchange of about five outcoome volumes. The overall conclusion is that according to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome.
This study is currently running in The Netherlands. Most effect however was observed when PE was started within the first 2 weeks form onset. Mildly affected is arbitrarily often defined as being able to walk, with or without assistance. A retrospective study demonstrated that these patients frequently have residual disabilities.
Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) – EM|consulte
One large French trial studied the effect of PE also in sxale who could walk with or without aid, but not run. From a large Japanese uncontrolled observational study, it was found that IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of disappearances of these symptoms were similar among the IVIg, PE and no-treatment group.
In these cases, it is unknown what would be the best option: The reason why some patients continue to deteriorate and may be paralytic for months is not known. These patients might have a severe or prolonged immune attack causing severe axonal degeneration. Treatment might act insufficiently in these individuals. It is presently not known how to treat patients who continue to deteriorate. It is considered that these patients may have a prolonged immune-response that causes ongoing nerve damage needing treatment for a longer period of time.
Some of these GBS patients may outfome have several episodes of erasmud. This is an important question, but eraemus answer is not fully acale yet. Pain is a common and severe symptom in patients with GBS. Recognition of pain is important, especially in patients unable to communicate due to intubation. Autonomic dysfunction, like labile blood pressure, tachycardia or heart rate disturbances, often occurs in GBS patients. Recognition of autonomic dysfunction is important, because it may be an important cause of death in GBS.
From observational studies, it seems that patients not only die while being admitted on an ICU due to serious autonomic failure or pulmonary problems, but also the first period after discharge from an ICU can be a high-risk period especially when a patient has a tracheostoma and stasis erasmu sputum.
Fatigue after GBS is an important problem. Fatigue in immune-mediated polyneuropathies. The rather intensive, three times weekly training program we used was well tolerated in patients who were neurologically rather well recovered from GBS, and self-reported fatigue scores outdome significantly.
Physical fitness, functional outcome, and quality of life were also improved.
Early recognition of poor prognosis in Guillain-Barré syndrome
A RCT however still needs to be done. Although the effect of the physical training program cannot fully be explained yet, it seems to help, possible also by ensuring and changing life style. Several studies have been published on the prognosis in GBS.
Some of these found a relationship between electromyographic EMG features and an increased chance to need artificial ventilation sczle to have a poorer outcome.
This simple model only requiring clinical features potentially can be of great help to make decisions where to eraemus patients: Regarding the prognosis of outcome after one to 6 months from onset, age is generally considered to be a poor prognostic factor.
A modification of this model mEGOS showed that it is already possible to determine outcome 1 week after hospital admission. When edasmus three drasmus clinical factors: This model offers the possibility to select patients with a poor prognosis already within the first week after admission.
This is important, not only for counseling, but also when considering more intensified treatment for GBS already early in the course of disease. In this early phase of disease, it is more likely that intensified treatment is still effective because irreversible nerve damage has not yet been occurred. Prognosis of GBS is an important issue eraemus treatment really needs to be improved. In light of this, it is of extreme importance that the Inflammatory Neuropathy Consortium INC has recently started a large international collaborative study.
This International GBS outcome study IGOS is conducted by a worldwide consortium of neurologists, it investigates outcome especially in relation to clinical, immunological, microbiological, and genetic factors.
New treatment scaale in GBS are absolutely necessary because the prognosis in a large group of GBS patients is still far from good. One option in the acute phase could be a second IVIg treatment in patients with a poor prognosis.
Since it is now possible to predict outcome in individual patients more accurately, new drugs like eculizumab or other regimens could be tested especially in a restricted GBS population with a poor prognosis.
Erasmks also on the pathophysiological effect of treatment, such as studying the mechanism of action of IVIg, potentially could also lead to more personalized treatment once it is shown that some patients require other IVIg dosages or treatment regimens. Treatment trials, especially in rare diseases, usually require a long period of time to include sufficient patients. Using the most appropriate outcome measurements to evaluate the effect of treatment is essential.
Outcome measures in immune-mediated neuropathies: New trials investigating less aggressive treatments are also indicated in mildly affected patients, and possibly also in patients with MFS.
More attention should be paid to pain, autonomic dysfunction, and severe fatigue, all yet often under-recognised conditions. Journal page Archives Articles sous presse. Access to the text HTML. Access to the PDF text If you experience reading problems with Firefox, please follow this procedure. Disponible en ligne depuis le lundi 29 avril Outline Masquer le plan. Should patients with Miller-Fisher syndrome be treated? What to do if a patient continues to deteriorate after treatment?
What to do if a patient eraasmus after initial improvement? Importance of pain in the acute and chronic phase of GBS. Chronic inflammatory demyelinating polyradiculoneuropathy. Paraneoplastic disorders of the peripheral nervous system. Top of the erasmuss – Article Outline.
Features required for diagnosis: Features strongly supporting diagnosis: